share_log

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target

HC Wainwright & Co.重申买入Capricor Therapeutics,维持40美元的目标股价
Benzinga ·  04/25 07:25

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $40 price target.

HC Wainwright & Co. 分析师约瑟夫·潘吉尼斯重申Capricor Therapeutics(纳斯达克股票代码:CAPR)的买入并维持40美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发